Titre : Complexe répresseur Polycomb-1

Complexe répresseur Polycomb-1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Recovery of Function
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Complexe répresseur Polycomb-1 : Questions médicales les plus fréquentes", "headline": "Complexe répresseur Polycomb-1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Complexe répresseur Polycomb-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-16", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Complexe répresseur Polycomb-1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines du groupe Polycomb", "url": "https://questionsmedicales.fr/mesh/D063146", "about": { "@type": "MedicalCondition", "name": "Protéines du groupe Polycomb", "code": { "@type": "MedicalCode", "code": "D063146", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.930.780.890" } } }, "about": { "@type": "MedicalCondition", "name": "Complexe répresseur Polycomb-1", "alternateName": "Polycomb Repressive Complex 1", "code": { "@type": "MedicalCode", "code": "D063150", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Haruhiko Koseki", "url": "https://questionsmedicales.fr/author/Haruhiko%20Koseki", "affiliation": { "@type": "Organization", "name": "Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences (RIKEN-IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan; AMED-CREST, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan." } }, { "@type": "Person", "name": "Atsushi Iwama", "url": "https://questionsmedicales.fr/author/Atsushi%20Iwama", "affiliation": { "@type": "Organization", "name": "Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan." } }, { "@type": "Person", "name": "Elena Ezhkova", "url": "https://questionsmedicales.fr/author/Elena%20Ezhkova", "affiliation": { "@type": "Organization", "name": "Black Family Stem Cell Institute, The Tisch Cancer Institute, Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: elena.ezhkova@mssm.edu." } }, { "@type": "Person", "name": "Claudia Köhler", "url": "https://questionsmedicales.fr/author/Claudia%20K%C3%B6hler", "affiliation": { "@type": "Organization", "name": "Department of Plant Biology, Swedish University of Agricultural Sciences and Linnean Center for Plant Biology, 75007, Uppsala, Sweden. koehler@mpimp-golm.mpg.de." } }, { "@type": "Person", "name": "Lars Hennig", "url": "https://questionsmedicales.fr/author/Lars%20Hennig", "affiliation": { "@type": "Organization", "name": "Department of Plant Biology, Swedish University of Agricultural Sciences and Linnean Center for Plant Biology, 75007, Uppsala, Sweden." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Application Effectiveness of Segment IV Portal Vein Reconstruction for Early Postoperative Liver Function Recovery in Split Liver Transplantation.", "datePublished": "2023-04-26", "url": "https://questionsmedicales.fr/article/37181788", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/ti.2023.10808" } }, { "@type": "ScholarlyArticle", "name": "Super resolution imaging reconstruction reveals that gold standard methods may not correctly conclude neural/brain functional recovery.", "datePublished": "2023-02-14", "url": "https://questionsmedicales.fr/article/36805708", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.compmedimag.2023.102198" } }, { "@type": "ScholarlyArticle", "name": "Application of a novel nested ensemble algorithm in predicting motor function recovery in patients with traumatic cervical spinal cord injury.", "datePublished": "2024-07-29", "url": "https://questionsmedicales.fr/article/39075134", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-65755-1" } }, { "@type": "ScholarlyArticle", "name": "Zinc regulates a specific subpopulation of VEGFA + microglia to improve the hypoxic microenvironment for functional recovery after spinal cord injury.", "datePublished": "2023-10-24", "url": "https://questionsmedicales.fr/article/37883817", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.intimp.2023.111092" } }, { "@type": "ScholarlyArticle", "name": "Mesencephalic astrocyte-derived neurotrophic factor promotes axonal regeneration and the motor function recovery after sciatic nerve injury.", "datePublished": "2023-06-17", "url": "https://questionsmedicales.fr/article/37393642", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.bbrc.2023.06.056" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Facteurs de transcription", "item": "https://questionsmedicales.fr/mesh/D014157" }, { "@type": "ListItem", "position": 5, "name": "Protéines de répression", "item": "https://questionsmedicales.fr/mesh/D012097" }, { "@type": "ListItem", "position": 6, "name": "Protéines du groupe Polycomb", "item": "https://questionsmedicales.fr/mesh/D063146" }, { "@type": "ListItem", "position": 7, "name": "Complexe répresseur Polycomb-1", "item": "https://questionsmedicales.fr/mesh/D063150" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Complexe répresseur Polycomb-1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Complexe répresseur Polycomb-1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Complexe répresseur Polycomb-1", "description": "Comment diagnostiquer une dysfonction du PRC1 ?\nQuels tests sont utilisés pour évaluer le PRC1 ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels marqueurs sont associés au PRC1 ?\nLe diagnostic est-il basé sur des symptômes cliniques ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=8#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Complexe répresseur Polycomb-1", "description": "Quels symptômes indiquent une anomalie du PRC1 ?\nLe PRC1 est-il lié à des cancers spécifiques ?\nLes troubles neurologiques sont-ils liés au PRC1 ?\nLe PRC1 affecte-t-il le métabolisme ?\nY a-t-il des symptômes généraux associés au PRC1 ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=8#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Complexe répresseur Polycomb-1", "description": "Peut-on prévenir les anomalies liées au PRC1 ?\nY a-t-il des tests de dépistage pour le PRC1 ?\nLes antécédents familiaux influencent-ils le risque ?\nDes conseils génétiques sont-ils disponibles ?\nL'alimentation joue-t-elle un rôle dans la prévention ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=8#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Complexe répresseur Polycomb-1", "description": "Quels traitements ciblent le PRC1 ?\nLa chimiothérapie est-elle efficace contre les anomalies du PRC1 ?\nDes traitements expérimentaux existent-ils pour le PRC1 ?\nLe PRC1 peut-il être ciblé par des médicaments spécifiques ?\nLes thérapies combinées sont-elles efficaces pour le PRC1 ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=8#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Complexe répresseur Polycomb-1", "description": "Quelles complications peuvent survenir avec le PRC1 ?\nLe PRC1 est-il lié à des maladies auto-immunes ?\nLes complications sont-elles réversibles ?\nLe PRC1 affecte-t-il la qualité de vie ?\nY a-t-il des complications neurologiques associées ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=8#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Complexe répresseur Polycomb-1", "description": "Quels sont les facteurs de risque pour le PRC1 ?\nL'âge est-il un facteur de risque pour le PRC1 ?\nLes facteurs environnementaux influencent-ils le PRC1 ?\nLe sexe joue-t-il un rôle dans le risque de PRC1 ?\nLe mode de vie influence-t-il le risque de PRC1 ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=8#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction du PRC1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des analyses génétiques et des études d'expression génique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer le PRC1 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de séquençage et des analyses de chromatine sont couramment utilisés." } }, { "@type": "Question", "name": "Le diagnostic nécessite-t-il une biopsie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie peut être nécessaire pour analyser les tissus affectés par le PRC1." } }, { "@type": "Question", "name": "Quels marqueurs sont associés au PRC1 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs épigénétiques comme les modifications des histones sont souvent analysés." } }, { "@type": "Question", "name": "Le diagnostic est-il basé sur des symptômes cliniques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes cliniques peuvent orienter le diagnostic, mais des tests spécifiques sont nécessaires." } }, { "@type": "Question", "name": "Quels symptômes indiquent une anomalie du PRC1 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies de développement et des troubles de la différenciation cellulaire peuvent survenir." } }, { "@type": "Question", "name": "Le PRC1 est-il lié à des cancers spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations dans le PRC1 sont associées à divers types de cancers, notamment le cancer du sein." } }, { "@type": "Question", "name": "Les troubles neurologiques sont-ils liés au PRC1 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent un lien entre le PRC1 et des troubles neurologiques, mais les recherches sont en cours." } }, { "@type": "Question", "name": "Le PRC1 affecte-t-il le métabolisme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches indiquent que le PRC1 peut influencer le métabolisme cellulaire et énergétique." } }, { "@type": "Question", "name": "Y a-t-il des symptômes généraux associés au PRC1 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue et des anomalies de croissance peuvent être observés." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies liées au PRC1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire certains risques." } }, { "@type": "Question", "name": "Y a-t-il des tests de dépistage pour le PRC1 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de tests de dépistage standardisés pour les anomalies du PRC1." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque d'anomalies du PRC1." } }, { "@type": "Question", "name": "Des conseils génétiques sont-ils disponibles ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils génétiques peuvent aider à évaluer le risque et à discuter des options de prévention." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut contribuer à la santé cellulaire, mais ne prévient pas spécifiquement les anomalies du PRC1." } }, { "@type": "Question", "name": "Quels traitements ciblent le PRC1 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de la méthylation des histones et des thérapies géniques sont explorés." } }, { "@type": "Question", "name": "La chimiothérapie est-elle efficace contre les anomalies du PRC1 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie peut être utilisée, mais son efficacité dépend du type de cancer associé." } }, { "@type": "Question", "name": "Des traitements expérimentaux existent-ils pour le PRC1 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements expérimentaux sont en cours d'évaluation dans des essais cliniques." } }, { "@type": "Question", "name": "Le PRC1 peut-il être ciblé par des médicaments spécifiques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours pour développer des médicaments ciblant spécifiquement le PRC1." } }, { "@type": "Question", "name": "Les thérapies combinées sont-elles efficaces pour le PRC1 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies combinées peuvent améliorer l'efficacité des traitements contre les cancers liés au PRC1." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le PRC1 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des cancers avancés et des troubles de développement sévères." } }, { "@type": "Question", "name": "Le PRC1 est-il lié à des maladies auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien potentiel entre le PRC1 et certaines maladies auto-immunes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Le PRC1 affecte-t-il la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anomalies du PRC1 peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des complications neurologiques associées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies du PRC1 peuvent entraîner des complications neurologiques, comme des troubles cognitifs." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour le PRC1 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des mutations génétiques, des antécédents familiaux et des expositions environnementales." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour le PRC1 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains types de cancers liés au PRC1 sont plus fréquents chez les personnes âgées." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils le PRC1 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des expositions à des agents cancérigènes peuvent augmenter le risque d'anomalies du PRC1." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque de PRC1 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains cancers liés au PRC1 montrent des différences de prévalence entre les sexes." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque de PRC1 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie malsain, comme le tabagisme, peut augmenter le risque d'anomalies du PRC1." } } ] } ] }

Sources (10000 au total)

Zinc regulates a specific subpopulation of VEGFA + microglia to improve the hypoxic microenvironment for functional recovery after spinal cord injury.

Spinal cord injury (SCI) is a central nervous system injury that is primarily traumatic and manifests as autonomic dysfunction below the level of injury. Our previous studies have found that zinc ions... We investigated the effect of zinc ions after spinal cord injury from the perspective of a hypoxic microenvironment, and elucidated the role of VEGF-A secreted by microglia for vascular regeneration a... Zinc promotes functional recovery after spinal cord injury by regulating VEGF-A secretion from microglia. On the one hand, VEGF-A secreted by microglia promotes angiogenesis through the PI3K/AKT/Bcl-2... Zinc promoted microglia secretion of VEGF-A, increased vascular endothelial cell proliferation and migration through the PI3K/AKT/Bcl-2 pathway, and inhibited microglia apoptosis....

Effect of Pelvic Floor Workout on Pelvic Floor Muscle Function Recovery of Postpartum Women: Protocol for a Randomized Controlled Trial.

There is a risk of pelvic floor dysfunction (PFD) from baby delivery. Many clinical guidelines recommend pelvic floor muscle training (PFMT) as the conservative treatment for PFD because pelvic floor ... The randomized controlled trial was projected to be conducted from November 2021 to March 2023. A total of 260 postpartum women would be recruited from the obstetrics departments of the study hospital... This trial will demonstrate that pelvic floor-care is accessible to most women and clinical practice on PFD may change relevantly should this study find that Online PEFLOW approach is effective to imp... ClinicalTrials.gov, NCT05218239....

Bacillus coagulans TBC169 probiotics for the recovery of intestinal function after gynecological laparoscopic surgery: a randomized, placebo-controlled trial.

Evidence suggests that Bacillus coagulans TBC169 can improve intestinal motility.... To investigate the effectiveness and safety of Bacillus coagulans TBC169 probiotics in promoting the recovery of intestinal function after gynecological laparoscopic surgery.... Patients who underwent laparoscopic surgeries due to gynecological diseases were randomly assigned to the high-dose, conventional-dose, and the placebo-control groups (1:1:1 ratio). The primary outcom... Compared to the placebo-control group, shorter FFT values were observed in the conventional-dose (23.15 h vs. 29.10 h, P < 0.05) and high-dose (19.15 h vs. 29.10 h, P < 0.001) groups. Similar trends w... Bacillus coagulans TBC169 probiotics can accelerate intestinal function recovery, and reduce postoperative adverse events in patients after gynecological laparoscopic surgery. The study protocol was r...

Urine Macrophages Polarization Predicts Renal Function Recovery after Nephron-Sparing Surgery in Patients with Renal Cell Carcinoma.

This study was conducted to investigate the underlying associations between urine macrophages polarization and renal function recovery after nephron-sparing surgery (NSS) in patients with renal cell c... Sixty-two patients with unilateral RCC who underwent NSS in our departments were prospectively recorded and followed up for long-term renal function to assess the onset of acute kidney injury (AKI) an... The cumulative incidence of postoperative AKI was 27.4% (17/62), and 47.0% (8/17) of those eventually developed to CKD during the follow-up. The mean urine M1/M2 ratio was 10.54 ± 8.13 in the AKI grou... Urine macrophages polarization could predict renal function recovery after NSS in patients with RCC. The urine M1/M2 ratio might a potential biomarker of RIRI but needs to be further verified in clini...

The effects of rehabilitation therapy duration on functional recovery of patients with subacute stroke stratified by individual's age: a retrospective multicenter study.

The duration of rehabilitation therapy is one of the key elements for promoting post-stroke functional recovery. However, whether an individual's age affects the effectiveness of the duration of rehab... This study aimed to investigate whether age has an influence on the relationship between the duration of rehabilitation therapy and post-stroke functional recovery.... This is a retrospective observational study.... Six convalescent inpatient rehabilitation hospitals in Japan.... The population of the study was represented by a total of 1186 participants with subacute stroke.... Participants were stratified into four groups according to their age (≤59, 60-69, 70-79, and ≥80 years). The data of minutes involved in performing rehabilitation therapy for participants during hospi... The mean FIM gains in the ≤59 years, 60-69 years, 70-79 years, and the ≥80 years groups were 38.7 (18.8), 32.8 (18.0), 29.7 (16.6), and 25.4 (17.2), respectively. The results of the multivariate regre... For patients with subacute stroke in rehabilitation hospitals, a higher duration of daily rehabilitation therapy was associated with better functional recovery in the 70-79 years group and ≥80 years g... An increased duration of daily rehabilitation therapy may be helpful in older adults with stroke selected for intensive rehabilitation for improvement of basic daily functioning....